The levels of four serum proteins, assayed by a radial immunodiffusion technique, have been measured in healthy women who had been given either the oestrogen or progestogen component of a combined oral contraceptive preparation for three weeks. Raised x2-macroglobulin and transferrin levels were found after oestrogen treatment but albumin and IgG did not significantly alter. In the progestogen-treated group all four proteins remained unchanged. The four proteins have also been assayed at frequent intervals during the normal menstrual cycle. No evidence of cyclical variation was found.
SYNOPSIS
The levels of four serum proteins, assayed by a radial immunodiffusion technique, have been measured in healthy women who had been given either the oestrogen or progestogen component of a combined oral contraceptive preparation for three weeks. Raised x2-macroglobulin and transferrin levels were found after oestrogen treatment but albumin and IgG did not significantly alter. In the progestogen-treated group all four proteins remained unchanged. The four proteins have also been assayed at frequent intervals during the normal menstrual cycle. No evidence of cyclical variation was found.
In a previous study using a radial immunodiffusion technique (Horne, Howie, Weir, and Goudie, 1970) we demonstrated significant increases in the levels of serum a2-macroglobulin, transferrin, and IgG in normal females who had received combined oestrogen/progestogen oral contraceptives. It therefore seemed of interest to determine whether these changes could be produced by the action of oestrogen or progestogen components administered alone and whether endogenous production of steroid hormones during the normal menstrual cycle caused physiological variation in the serum levels of these proteins.
Subjects and Methods
Two groups of 14 healthy females (mean ages 20-6 and 20-9 years, ranges 17-28 and 17-30) (Fahey and McKelvey, 1965; Mancini, Carbonara, and Heremans, 1965) . The specific antisera were prepared as described in a previous communication (Horne et al, 1970) . To minimize the effects of interplate variation (Thompson, Home, Steele, and Goudie, 1969) sera from any one subject were always tested in duplicate in a single assay plate in randomized wells. ' Absolute' values for each protein were calculated from a calibration curve prepared with solutions of a freeze-dried, reconstituted human serum containing 3, 6, 12, and 18 g protein per I00ml and standardized with reference to a Behringwerke serum containing specified concentrations of the proteins.
Total serum iron-binding capacity (TIBC) was measured by the method of Young and Hicks (1965) on sera obtained before and after three weeks' treatment with oestrogen and progestogen.
Results Table I shows that mestranol (M) leads to significant maximum increases in the serum levels of c%2-macroglobulin and transferrin of 23 % and 28 % above the pretreatment levels (p < 0-01). The increases were maximal one week after completion of treatment and even two weeks later the levels had not returned to the pretreatment levels. There (Table II) . 
Discussion
Our results clearly show that oestrogen is responsible for significant increases in a2-macroglobulin and transferrin of a similar order of magnitude to those found following administration of combined oral contraceptives in our previous study (Home et al, 1970) . Like Laurell, Kullander, and Thorell (1969) we do not find a significant effect of progestogen on transferrin levels whereas Briggs and Staniford (1969) have found an increase in total iron-binding capacity, presumably attributable to a rise in transferrin, following administration of progestogen. Furthermore, Musa, Doe, and Seal (1967) find no s increase in transferrin levels following oestrogen treatment in marked contrast to our findings. Unfortunately in all the above studies different synthetic steroid hormones have been used for varying periods. Since the other workers measured TIBC (Briggs and Staniford, 1969) and obtained different results, we wondered whether there might be a discrepancy between transferrin levels and TIBC following hormone therapy but in our cases this proved not to be so.
In our short-term experiments we have again found no significant change in albumin, which is known to fall by approximately 10% in patients receiving combined oral contraceptives for several months (H0nger and Rossing, 1969) .
We suspect that our previous finding of a 17% rise in serum IgG levels following combined oestrogen/ progestogen oral contraceptives is fortuitous. Laurell, Kullander and Thorell (1967) demonstrated no such increase nor have we in our present study with oestrogen and progestogen administered separately.
Finally our failure to demonstrate changes in the levels of these proteins during the menstrual cycle suggests that if physiological variations do occur they must be too small to be measured by our methods.
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